VM:CC - Voyageur Pharmaceuticals Signs LOI for Latin America Distribution Partnership Supporting Global Market Expansion

(TheNewswire)

Calgary, Alberta, Canada – TheNewswire - June 24, 2025 –Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTCPink:VYYRF) (“ Voyageur ”, or the “ Company ”), aCanadian public company developing cost-effective imaging contrastmedia, is pleased to announce the signing of a Non-binding Letter ofIntent (" LOI ") with a Latin American based specialty distributioncompany to establish a strategic partnership for the distribution andcommercialization of Voyageur’s radiology contrast media products.

The prospective partner is an establishedpharmaceutical distributor with a strong presence in Mexico and otherLatin American markets where Canadian regulatory approvals areaccepted. Upon final agreement, the distributor will lead marketing,sales and regulatory activities in the region. Final terms will bedisclosed upon the execution of a binding distribution agreement,which is expected within 90 days.

This partnership represents a key milestone inVoyageur’s international growth strategy, further expanding theCompany’s global footprint and supporting access to underservedmarkets with increasing demand for high-quality contrast media.“This agreement marks a significant step forward in ourcommercialization roadmap” said Brent Willis, CEO of Voyageur. “Itreflects our continued commitment to expanding global access to ourinnovative, cost-effective imaging solutions. Latin America is acritical market in our expansion plan, and this partnership lays thegroundwork for long term growth”

Sales of Voyageur’s barium sulfate contrast mediaproducts in Mexico and other Latin American countries will be subjectto local regulatory approval processes. The distributor is expected totake the lead in preparing and submitting necessary filings withsupport from Voyageur’s technical and regulatory team.

About Voyageur PharmaceuticalsLtd.

Voyageur, a Canadian public company trading under thesymbol VM on the TSX Venture Exchange, is in development of barium andiodine Active Pharmaceutical Ingredients (API) that offerhigh-performance and cost-effective imaging contrast agents. With astrategic focus on vertically integrating the barium and iodinecontrast markets, Voyageur aims to become a key player by producingits own barium and iodine. In addition, Voyageur is pursuing thedevelopment of new endo fullerene drugs.

Voyageur's business plan is set to generate cash flow by working withestablished third-party GMP pharmaceutical manufacturers in Canadathereby ensuring the validation of its products by regulatory agenciesworldwide. As Voyageur solidifies its presence in the market, it plansto transition into a high-margin domestic manufacturer of radiologydrugs.

At the core of its operations, Voyageur owns a 100%interest in the Frances Creek Project. Currently, the world'spharmaceutical barium sulphate is almost entirely syntheticallyproduced resulting in a less effective imaging quality product.Voyageur’s Frances Creek resource boasts a rare and exceptional grade mineral suitable for the pharmaceuticalmarketplace that Voyageur believes will replace the current syntheticproducts with higher quality imaging products.

Voyageur's ambitious vision is to become the firstvertically integrated company in the radiology contrast media drugmarket. By controlling all primary input costs, from the sourcing ofraw materials to final production, Voyageur believes it can ensurequality and cost efficiency. With its approach, it embodies the mottoof "From the Earth to the Bottle," highlighting Voyageur'scommitment to responsible sourcing and manufacturingpractices.

For Further Information:

Neither the TSX Venture Exchange nor its Regulation ServicesProvider (as that term is defined in the policies of the TSX VentureExchange) accepts responsibility for the adequacy or accuracy of thisnews release.

Cautionary Statement Regarding “Forward-Looking”Information

Thisnews release may contain certain forward-looking information andstatements, including without limitation, statements pertaining to:satisfactory completion of due diligence and the entering into of theAgreement; the Company's belief that it can become one of the first tooperate a fully-integrated iodine-based and barium-basedpharmaceutical manufacturing platform; the Company's aim to become akey player in the barium and iodine contrast markets, the Company'splan to transition into a high-margin domestic manufacturer ofradiology drugs; theCompany's belief that the Frances Creek Project's mineral will replacethe current synthetic products in the pharmaceutical marketplace withhigher quality imaging products; and the Company's belief that it canensure quality and cost efficiency by controlling all primary inputcosts. All statementsincluded herein, other than statements of historical fact, areforward-looking information and such information involves variousrisks and uncertainties. There can be no assurance that suchinformation will prove to be accurate, and actual results and futureevents could differ materially from those anticipated in suchinformation. A description of assumptions used to develop suchforward-looking information and a description of risk factors that maycause actual results to differ materially from forward-lookinginformation can be found in the Company's disclosure documents on theSEDAR+ website at www.sedarplus.ca. Voyageur does not undertake toupdate any forward-looking information except in accordance withapplicable securities laws.

Click Image To View Full Size

Copyright (c) 2025 TheNewswire - All rights reserved.